201 related articles for article (PubMed ID: 16882104)
1. Calcitonin gene-related peptide and somatostatin releases correlated with the area under the lafutidine concentration-time curve in human plasma.
Ikawa K; Shimatani T; Azuma Y; Inoue M; Morikawa N
J Clin Pharm Ther; 2006 Aug; 31(4):351-6. PubMed ID: 16882104
[TBL] [Abstract][Full Text] [Related]
2. Lafutidine, a novel histamine H2-receptor antagonist, increases serum calcitonin gene-related peptide in rats after water immersion-restraint stress.
Sato H; Kawashima K; Yuki M; Kazumori H; Rumi MA; Ortega-Cava CF; Ishihara S; Kinoshita Y
J Lab Clin Med; 2003 Feb; 141(2):102-5. PubMed ID: 12577045
[TBL] [Abstract][Full Text] [Related]
3. Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Nakamura M; Tazuma S; Ikawa K; Morikawa N
Dig Dis Sci; 2006 Jan; 51(1):114-20. PubMed ID: 16416222
[TBL] [Abstract][Full Text] [Related]
4. Lafutidine changes levels of somatostatin, calcitonin gene-related peptide, and secretin in human plasma.
Itoh H; Naito T; Takeyama M
Biol Pharm Bull; 2002 Mar; 25(3):379-82. PubMed ID: 11913538
[TBL] [Abstract][Full Text] [Related]
5. Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide.
Itoh H; Naito T; Takeyama M
J Pharm Pharmacol; 2002 Nov; 54(11):1559-63. PubMed ID: 12495560
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine.
Ikawa K; Shimatani T; Hayato S; Morikawa N; Tazuma S
Biol Pharm Bull; 2007 May; 30(5):1003-6. PubMed ID: 17473452
[TBL] [Abstract][Full Text] [Related]
7. Ecabet sodium raises plasma levels of calcitonin generelated peptide and substance P in healthy humans.
Katagiri F; Inoue S; Sato Y; Itoh H; Takeyama M
J Pharm Pharmacol; 2005 Jun; 57(6):799-805. PubMed ID: 15969937
[TBL] [Abstract][Full Text] [Related]
8. Lafutidine, a unique histamine H2-receptor antagonist, inhibits distention-induced gastric acid secretion through an H2 receptor-independent mechanism.
Nakano M; Kitano S; Nanri M; Kiniwa M
Eur J Pharmacol; 2011 May; 658(2-3):236-41. PubMed ID: 21349265
[TBL] [Abstract][Full Text] [Related]
9. Sensitizing effects of lafutidine on CGRP-containing afferent nerves in the rat stomach.
Nishihara K; Nozawa Y; Nakano M; Ajioka H; Matsuura N
Br J Pharmacol; 2002 Mar; 135(6):1487-94. PubMed ID: 11906962
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.
Suzuki T; Kagami T; Uotani T; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Eur J Clin Pharmacol; 2018 Jan; 74(1):45-52. PubMed ID: 28986609
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of neutrophil activation by lafutidine, an H2-receptor antagonist, through enhancement of sensory neuron activation contributes to the reduction of stress-induced gastric mucosal injury in rats.
Harada N; Okajima K
Dig Dis Sci; 2007 Feb; 52(2):469-77. PubMed ID: 17211693
[TBL] [Abstract][Full Text] [Related]
12. Lafutidine increases hepatic blood flow via potentiating the action of central thyrotropin-releasing hormone in rats.
Yoneda M; Kurosawa M; Watanobe H; Terano A
J Gastroenterol Hepatol; 2003 Feb; 18(2):177-84. PubMed ID: 12542603
[TBL] [Abstract][Full Text] [Related]
13. Effect of Helicobacter pylori status on intragastric pH during administration of lafutidine or famotidine.
Koike T; Ohara S; Sehine H; Kawamura M; Abe Y; Inomata Y; Iijima K; Imatani A; Shimosegawa T
Hepatogastroenterology; 2007 Jun; 54(76):1280-4. PubMed ID: 17629089
[TBL] [Abstract][Full Text] [Related]
14. Lafutidine inhibits Helicobacter pylori-induced interleukin-8 production in human gastric epithelial cells.
Nozawa Y; Nishihara K; Akizawa Y; Orimoto N; Nakano M; Uji T; Ajioka H; Kanda A; Matsuura N; Kiniwa M
J Gastroenterol Hepatol; 2004 May; 19(5):506-11. PubMed ID: 15086593
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats.
Amagase K; Ochi A; Sugihara T; Kato S; Takeuchi K
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S111-8. PubMed ID: 20586851
[TBL] [Abstract][Full Text] [Related]
16. Effect of pilocarpine on substance P and calcitonin gene-related peptide releases correlate with salivary secretion in human saliva and plasma.
Sato Y; Itoh H; Suzuki Y; Tatsuta R; Takeyama M
J Clin Pharm Ther; 2013 Feb; 38(1):19-23. PubMed ID: 23030252
[TBL] [Abstract][Full Text] [Related]
17. Effects of a novel histamine H2-receptor antagonist, lafutidine, on the mucus barrier of human gastric mucosa.
Ichikawa T; Ota H; Sugiyama A; Maruta F; Ikezawa T; Hotta K; Ishihara K
J Gastroenterol Hepatol; 2007 Nov; 22(11):1800-5. PubMed ID: 17914953
[TBL] [Abstract][Full Text] [Related]
18. Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.
Yamagishi H; Koike T; Ohara S; Horii T; Kikuchi R; Kobayashi S; Abe Y; Iijima K; Imatani A; Suzuki K; Hishinuma T; Goto J; Shimosegawa T
World J Gastroenterol; 2008 Apr; 14(15):2406-10. PubMed ID: 18416470
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopharmacological study of gastrointestinal drugs from the viewpoint of postmarketing development].
Itoh H
Yakugaku Zasshi; 2006 Sep; 126(9):767-78. PubMed ID: 16946590
[TBL] [Abstract][Full Text] [Related]
20. Palliative effect of lafutidine on oral burning sensation.
Toida M; Kato K; Makita H; Long NK; Takeda T; Hatakeyama D; Yamashita T; Shibata T
J Oral Pathol Med; 2009 Mar; 38(3):262-8. PubMed ID: 19175712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
